Binswanger IA, Shetterly SM, Xu S, Narwaney KJ, McClure DL, Rinehart DJ, Nguyen AP (2022) & J. M. J. J. N. O. Glanz Opioid Dose Trajectories and Associations With Mortality, Opioid Use Disorder, Continued Opioid Therapy, and Health Plan Disenrollment. 5, e2234671-e2234671

Cohen SP, Vase L, Hooten WMJTL (2021) Chronic pain: an update on burden, best practices, and new advances. 397, 2082–2097

Dehong X, Wenmei W, Siqin H, Peng Z, Xianchun W, Xiongzhi ZJC (2022) Effects of JZTX-V on the wild type Kv4. 3 expressed in HEK293T and molecular determinants in the voltage-sensing domains of Kv4. 3 interacting with JZTX-V. 16:72–83

Hwang S-M, Jo Y-Y, Cohen CF, Kim Y-H, Berta T (2022) & C.-K. J. I. J. o. M. S. Park Venom Peptide Toxins Targeting the Outer Pore Region of Transient Receptor Potential Vanilloid 1 in Pain: Implications for Analgesic Drug Development. 23, 5772

J. P. M. Freo U (2022) Paracetamol for multimodal analgesia. 12:737–750

King J, Emrick JJ, Kelly M, Herzig V, King GF, Medzihradszky KF, Julius DJC (2019) A cell-penetrating Scorpion Toxin enables Mode-Specific Modulation of TRPA1 and Pain - ScienceDirect. 178:1362–1374e16

Langenegger N, Nentwig W, Kuhn-Nentwig LJT (2019) Spider venom: components, modes of action, and novel strategies in Transcriptomic and proteomic analyses. 11:611

Laskin DM, Block SJ (1986) Diagnosis and treatment of myofacial pain-dysfunction (MPD) syndrome. 56, 75–84

Lne A, Azm BJP (2019) Inflammatory mediators of opioid tolerance: implications for dependency and addiction. 115:51–58

Lopes A, Menezes MS (2021) & G. B. J. B. J. o. Anesthesiology Chronic postoperative pain: ubiquitous and scarcely appraised – narrative review

Moyer BD, Murray JK, Joseph L, Kristin A, Philippe F, Jordan JB, Lee JH, Liu D, Long J, Kelvin SJPO (2018) Pharmacological characterization of potent and selective NaV1.7 inhibitors engineered from Chilobrachys Jingzhao tarantula venom peptide JzTx-V. 13, e0196791

Rosenberger DC, Blechschmidt V, Timmerman H, Wolff A (2020) & R.-D. J. J. o. N. T. Treede Challenges of neuropathic pain: focus on diabetic neuropathy. 127, 589–624

Saez NJ, Senff S, Jensen JE, Er SY (2010) & G. F. J. T. King Spider-Venom Peptides as Therapeutics. 2, 2851–2871

Shaheed CA, Beardsley J, Day RO (2022) Immunomodulatory effects of pharmaceutical opioids and antipyretic analgesics. & A. J. J. B. J. o. C. P. Mclachlan. Mechanisms and relevance to infection

Uramaru N, Shigematsu H, Toda A, Eyanagi R, Kitamura S, Ohta SJJ (2010) Design, synthesis, and pharmacological activity of nonallergenic pyrazolone-type antipyretic analgesics. 53, 8727-33

Varga Z, Tajti G, Panyi GJBF (2021) The Kv1.3 K + channel in the immune system and its precision pharmacology using peptide toxins. 72

Verkest C, Salinas M, Diochot S, Deval E, Lingueglia E, Baron AJT (2022) Mechanisms of action of the peptide toxins Targeting Human and Rodent Acid-sensing Ion channels and relevance to their in vivo Analgesic effects. 14:709

Woolf CJ (2010) J. T. J. o. c. i. What is this thing called pain? 120, 3742–3744

Yiya Z, Ji, Luo J, He (2019) Mingqiang, Rong, Xiongzhi & Z. J. F. i. pharmacology JZTX-V Targets the Voltage Sensor in Kv4.2 to Inhibit I < sub > to Potassium Channels in Cardiomyocytes

Yuan C, Yang S, Liao Z, Liang SJB, b. r. communications (2007) Effects and mechanism of Chinese tarantula toxins on the Kv2. 1 potassium channels. 352:799–804

Zeng X, Deng M, Lin Y, Yuan C, Pi J, Liang SJT (2007) Isolation and characterization of Jingzhaotoxin-V, a novel neurotoxin from the venom of the spider Chilobrachys Jingzhao. 49:388–399